IL274248B2 - Compounds and preparations for the treatment of hematological disorders - Google Patents

Compounds and preparations for the treatment of hematological disorders

Info

Publication number
IL274248B2
IL274248B2 IL274248A IL27424820A IL274248B2 IL 274248 B2 IL274248 B2 IL 274248B2 IL 274248 A IL274248 A IL 274248A IL 27424820 A IL27424820 A IL 27424820A IL 274248 B2 IL274248 B2 IL 274248B2
Authority
IL
Israel
Prior art keywords
compound
leukemia
lymphoma
nhl
dlbcl
Prior art date
Application number
IL274248A
Other languages
English (en)
Hebrew (he)
Other versions
IL274248A (en
IL274248B1 (en
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of IL274248A publication Critical patent/IL274248A/en
Publication of IL274248B1 publication Critical patent/IL274248B1/en
Publication of IL274248B2 publication Critical patent/IL274248B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL274248A 2017-10-31 2018-10-30 Compounds and preparations for the treatment of hematological disorders IL274248B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762579502P 2017-10-31 2017-10-31
PCT/US2018/058194 WO2019089580A1 (en) 2017-10-31 2018-10-30 Compounds and compositions for treating hematological disorders

Publications (3)

Publication Number Publication Date
IL274248A IL274248A (en) 2020-06-30
IL274248B1 IL274248B1 (en) 2024-02-01
IL274248B2 true IL274248B2 (en) 2024-06-01

Family

ID=66328095

Family Applications (3)

Application Number Title Priority Date Filing Date
IL274248A IL274248B2 (en) 2017-10-31 2018-10-30 Compounds and preparations for the treatment of hematological disorders
IL308364A IL308364B2 (en) 2017-10-31 2018-10-30 Compounds and preparations for the treatment of hematological disorders
IL315025A IL315025A (en) 2017-10-31 2018-10-30 Compounds and preparations for the treatment of hematological disorders

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL308364A IL308364B2 (en) 2017-10-31 2018-10-30 Compounds and preparations for the treatment of hematological disorders
IL315025A IL315025A (en) 2017-10-31 2018-10-30 Compounds and preparations for the treatment of hematological disorders

Country Status (26)

Country Link
US (3) US10758518B2 (enExample)
EP (2) EP3704108B1 (enExample)
JP (3) JP7241747B2 (enExample)
KR (2) KR102697663B1 (enExample)
CN (2) CN111225911B (enExample)
AU (3) AU2018359248B2 (enExample)
BR (1) BR112020008214A2 (enExample)
CA (1) CA3079628A1 (enExample)
DK (1) DK3704108T3 (enExample)
EA (1) EA202090497A1 (enExample)
ES (1) ES2979273T3 (enExample)
FI (1) FI3704108T3 (enExample)
HR (1) HRP20240700T1 (enExample)
HU (1) HUE067356T2 (enExample)
IL (3) IL274248B2 (enExample)
LT (1) LT3704108T (enExample)
MX (2) MX2020003666A (enExample)
MY (1) MY203827A (enExample)
PH (1) PH12020550457A1 (enExample)
PL (1) PL3704108T3 (enExample)
PT (1) PT3704108T (enExample)
RS (1) RS65572B1 (enExample)
SG (1) SG11202002386WA (enExample)
SI (1) SI3704108T1 (enExample)
SM (1) SMT202400216T1 (enExample)
WO (1) WO2019089580A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015205374B2 (en) 2014-01-13 2018-08-23 Aurigene Oncology Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
SG11201908171TA (en) 2017-03-31 2019-10-30 Aurigene Discovery Tech Ltd Compounds and compositions for treating hematological disorders
SI3704108T1 (sl) * 2017-10-31 2024-07-31 Curis, Inc. Inhibitor irak4 v kombinaciji z inhibitorjem bcl-2 za uporabo pri zdravljenju raka
EP4015513B1 (en) * 2019-09-24 2023-11-01 Shanghai Meiyue Biotech Development Co., Ltd. Irak inhibitor and preparation method therefor and use thereof
US20230151025A1 (en) 2020-04-07 2023-05-18 Bayer Aktiengesellschaft Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances
JP2023537477A (ja) * 2020-08-03 2023-09-01 キュリス，インコーポレイテッド 疾患及び障害を治療するための組成物及び方法
CA3199157A1 (en) * 2020-11-18 2022-05-27 Reinhard Von Roemeling Methods of treating diseases and disorders
WO2022135338A1 (zh) * 2020-12-25 2022-06-30 南京明德新药研发有限公司 酰胺噁唑类化合物
CA3214747A1 (en) * 2021-04-08 2022-10-13 Reinhard Von Roemeling Combination therapies for the treatment of cancer
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
TW202328150A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途
TW202328151A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途
EP4434981A4 (en) * 2021-12-23 2025-08-20 Hangzhou Polymed Biopharmaceuticals Inc FIVE- AND SIX-MEMBERED COMPOUND, ITS PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION AND ITS USE
WO2025090844A1 (en) * 2023-10-27 2025-05-01 Curis, Inc. Methods of treating cancer associated with reduced interleukin 1 beta expression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014190163A2 (en) * 2013-05-22 2014-11-27 Children's Hospital Medical Center Combination therapy for mds
WO2015104688A1 (en) * 2014-01-13 2015-07-16 Aurigene Discovery Technologies Limited Bicyclic heterocyclyl derivatives as irak4 inhibitors
WO2017023941A1 (en) * 2015-08-04 2017-02-09 Rigel Pharmaceuticals, Inc. Benzazole compounds and methods for making and using the compounds

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
HU222234B1 (hu) 1990-05-18 2003-05-28 Aventis Pharma Deutschland Gmbh. Eljárás izoxazol-4-karbonsav-amidok és hidroxi-alkilidén-cián-ecetsav-amidok, a vegyületeket tartalmazó gyógyászati készítmények és az ismert vegyületeket tartalmazó rákellenes hatású gyógyszerkészítmények előállítására
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
CN100408100C (zh) 1997-07-29 2008-08-06 阿尔康实验室公司 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
EP1051167A1 (en) 1998-01-29 2000-11-15 Sepracor, Inc. Pharmaceutical uses of optically pure (-) -bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
DE10023486C1 (de) 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
AU2004236240C1 (en) 2003-05-01 2010-11-04 Bristol-Myers Squibb Company Aryl-substituted pyrazole compounds useful as kinase inhibitors
ATE556067T1 (de) 2003-05-20 2012-05-15 Ajinomoto Kk Modulatoren des vanilloid rezeptors
US20050004133A1 (en) 2003-06-05 2005-01-06 Makings Lewis R. Modulators of VR1 receptor
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050197364A1 (en) 2003-10-07 2005-09-08 Kelly Michael G. Amide compounds as ion channel ligands and uses thereof
WO2005107460A1 (en) 2004-04-22 2005-11-17 Bayer Cropscience Lp Method and composition for controlling weeds
EP1655297A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
WO2006053227A2 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
BRPI0519124A2 (pt) 2004-12-17 2008-12-23 Lilly Co Eli composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
US7838543B2 (en) 2004-12-17 2010-11-23 Eli Lilly And Company MCH receptor antagonists
EP1674467A1 (en) 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
CA2641744C (en) 2006-02-10 2012-09-25 Transtech Pharma, Inc. Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
GB0606429D0 (en) 2006-03-30 2006-05-10 Novartis Ag Organic compounds
WO2007117465A2 (en) 2006-03-31 2007-10-18 Abbott Laboratories Indazole compounds
WO2007121154A2 (en) 2006-04-11 2007-10-25 Janssen Pharmaceutica, N.V. Substituted benzothiazole kinase inhibitors
US20110021513A1 (en) 2006-09-07 2011-01-27 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
US8293923B2 (en) 2006-09-07 2012-10-23 Biogen Idec Ma Inc. Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
US20080153810A1 (en) 2006-11-15 2008-06-26 Forest Laboratories Holdings Limited Indazole derivatives useful as melanin concentrating receptor ligands
US7998995B2 (en) 2006-12-08 2011-08-16 Exelixis Patent Company Llc LXR and FXR modulators
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
WO2009012312A1 (en) 2007-07-16 2009-01-22 Abbott Laboratories Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
KR20100051849A (ko) 2007-08-08 2010-05-18 메르크 세로노 에스. 에이. 다발성 경화증의 치료를 위한 스핑고신-1-포스페이트(ｓ1ｐ)수용체에 결합하는 6-아미노-피리미딘-4-카르복스아미드 유도체 및 이와 관련된 화합물
AU2009215191A1 (en) 2008-02-13 2009-08-20 Gilead Connecticut, Inc. 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
WO2010059602A2 (en) 2008-11-19 2010-05-27 Schering Corporation Inhibitors of diacylglycerol acyltransferase
US8283360B2 (en) 2008-12-19 2012-10-09 Merck Sharp & Dohme Corp. Bicyclic heterocyclic derivatives and methods of use thereof
SG172382A1 (en) 2008-12-23 2011-07-28 Hoffmann La Roche Dihydropyridone ureas as p2x7 modulators
EP2488486B1 (en) 2009-10-13 2019-08-14 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
WO2011133750A1 (en) 2010-04-22 2011-10-27 Janssen Pharmaceutica Nv Indazole compounds useful as ketohexokinase inhibitors
EP2563358A4 (en) 2010-04-30 2013-09-25 Merck Sharp & Dohme INHIBITORS OF PHOSPHOINOSITIDE-DEPENDENT KINASE 1 (PDK1)
WO2011163640A1 (en) 2010-06-24 2011-12-29 Chemocentryx, Inc. C5ar antagonists
WO2012007375A1 (en) 2010-07-13 2012-01-19 F. Hoffmann-La Roche Ag Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators
EP2640708A1 (en) 2010-11-19 2013-09-25 Ligand Pharmaceuticals Inc. Heterocycle amines and uses thereof
HRP20161127T1 (hr) 2010-12-20 2016-11-18 Merck Serono S.A. Derivati indazolil triazola kao inhibitori irak
CN106974913A (zh) 2011-04-12 2017-07-25 美国卫生和人力服务部 用于治疗或预防疟疾的疟原虫表面阴离子通道抑制剂
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
CA2852936A1 (en) 2011-10-20 2013-04-25 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
GB201119401D0 (en) 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
KR101385603B1 (ko) 2012-05-17 2014-04-21 한국원자력의학원 벤조티아졸 유도체 및 암 치료를 위한 그의 용도
WO2014003483A1 (en) 2012-06-29 2014-01-03 Hanmi Pharm. Co., Ltd. Fused pyrimidine derivatives having inhibitory activity on fms kinases
WO2014011902A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US9334249B2 (en) 2012-11-03 2016-05-10 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
AU2015205348A1 (en) 2014-01-10 2016-07-28 Aurigene Discovery Technologies Limited Indazole compounds as IRAK4 inhibitors
JP6532474B2 (ja) 2014-02-06 2019-06-19 アッヴィ・インコーポレイテッド ６−ヘテロアリールオキシ−および６−アリールオキシ−キノリン−２−カルボキシアミドならびにその使用
EA201692418A1 (ru) * 2014-06-20 2017-04-28 Ауриджен Дискавери Текнолоджиз Лимитед Замещенные индазольные соединения в качестве irak4 ингибиторов
BR112018000635A2 (pt) 2015-07-15 2018-09-18 Aurigene Discovery Tech Ltd compostos aza substituídos como inibidores irak-4
EA201890307A1 (ru) 2015-07-15 2018-10-31 Ориджин Дискавери Текнолоджиз Лимитед Индазольные и азаиндазольные соединения как ингибиторы irak-4
CA3038130A1 (en) 2016-10-28 2018-05-03 Children's Hospital Medical Center Treatment of diseases associated with activated irak
SI3704108T1 (sl) * 2017-10-31 2024-07-31 Curis, Inc. Inhibitor irak4 v kombinaciji z inhibitorjem bcl-2 za uporabo pri zdravljenju raka

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014190163A2 (en) * 2013-05-22 2014-11-27 Children's Hospital Medical Center Combination therapy for mds
WO2015104688A1 (en) * 2014-01-13 2015-07-16 Aurigene Discovery Technologies Limited Bicyclic heterocyclyl derivatives as irak4 inhibitors
WO2017023941A1 (en) * 2015-08-04 2017-02-09 Rigel Pharmaceuticals, Inc. Benzazole compounds and methods for making and using the compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOOHER ROBERT ET AL:, COMBINATION OF IRAK4 INHIBITOR CA-4948 WITHBCL2 INHIBITOR VENETOCLAX INDUCES TUMOR REGRESSION IN AN ABC-DLBCLXENOGRAFT MODEL, 8 December 2017 (2017-12-08) *

Also Published As

Publication number Publication date
EP4410377A2 (en) 2024-08-07
JP7241747B2 (ja) 2023-03-17
AU2025205341A1 (en) 2025-07-31
IL315025A (en) 2024-10-01
EP3704108B1 (en) 2024-04-24
EP3704108A1 (en) 2020-09-09
CN111225911B (zh) 2023-09-01
MX2020003666A (es) 2020-08-03
BR112020008214A2 (pt) 2020-10-27
KR102697663B1 (ko) 2024-08-21
HRP20240700T1 (hr) 2024-08-16
MX2023010882A (es) 2023-09-27
US20220370422A1 (en) 2022-11-24
JP7476380B2 (ja) 2024-04-30
JP2024096919A (ja) 2024-07-17
LT3704108T (lt) 2024-06-25
IL308364A (en) 2024-01-01
HUE067356T2 (hu) 2024-10-28
ES2979273T3 (es) 2024-09-25
CA3079628A1 (en) 2019-05-09
WO2019089580A1 (en) 2019-05-09
PT3704108T (pt) 2024-06-11
IL274248A (en) 2020-06-30
IL308364B1 (en) 2024-10-01
KR20200080254A (ko) 2020-07-06
CN111225911A (zh) 2020-06-02
AU2018359248B2 (en) 2023-06-01
JP2023071915A (ja) 2023-05-23
IL308364B2 (en) 2025-02-01
RS65572B1 (sr) 2024-06-28
US20190134010A1 (en) 2019-05-09
CN117064897A (zh) 2023-11-17
EA202090497A1 (ru) 2020-11-23
FI3704108T3 (fi) 2024-05-23
AU2018359248A1 (en) 2020-03-26
JP2021501145A (ja) 2021-01-14
SMT202400216T1 (it) 2024-07-09
US10758518B2 (en) 2020-09-01
MY203827A (en) 2024-07-19
US20200345704A1 (en) 2020-11-05
NZ762393A (en) 2025-07-25
EP3704108A4 (en) 2021-08-25
DK3704108T3 (da) 2024-06-10
AU2023222890A1 (en) 2023-09-14
SG11202002386WA (en) 2020-04-29
SI3704108T1 (sl) 2024-07-31
PL3704108T3 (pl) 2024-07-22
PH12020550457A1 (en) 2021-03-22
AU2023222890B2 (en) 2025-04-17
EP4410377A3 (en) 2024-11-13
IL274248B1 (en) 2024-02-01
KR20240130818A (ko) 2024-08-29

Similar Documents

Publication Publication Date Title
IL274248B2 (en) Compounds and preparations for the treatment of hematological disorders
PH12019502138A1 (en) Compounds and compositions for treating hematological disorders
MX2019001043A (es) Metodos y composiciones para el tratamiento de la mielofibrosis.
MX2023005160A (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
PH12022551546A1 (en) Carboxy derivatives with antiinflamatory properties.
PH12022550286A1 (en) Deuterated compounds for use in the treatment of cancer
GEAP202215535A (en) Compounds
MX2021003478A (es) Compuestos utiles como inhibidores de cinasa.
GEP20247646B (en) Substituted aminoquinolones as dgkalpha inhibitors for immune activation
NZ596583A (en) Substituted dihydropyrazolones for treating cardiovascular and haematological diseases
MX2014014831A (es) Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer.
NZ708249A (en) Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
MX2019015204A (es) Uso del anticuerpo anti-cd70 argx-110 para el tratamiento de leucemia mieloide aguda.
MY198004A (en) Antitumoral compounds
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
MX2019006079A (es) Derivados de oxoisoquinolina novedosos.
IN2012DN01983A (enExample)
MX2019002019A (es) Compuestos de beta-amino-isoquinolinil amida.
MX2020001979A (es) Macrociclo que contiene aminopirazol y pirimidina y composicion farmaceutica y uso de la misma.
WO2016018511A3 (en) Methods and compositions for treatment of her-positive cancers
MX2018011046A (es) Composiciones y metodos para tratar canceres.
WO2017040801A3 (en) Methods for making and using an immunoconjugate for the treatment of cancer
SA515370253B1 (ar) مركب أميد عطري غير متجانس الحلقة يحتوي على نتروجين ثنائي الحلقة
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer